Targeting O -GlcNAcylation in cancer therapeutic resistance: The sugar Saga continues
Lulu Chen,Mengxue Hu,Luojun Chen,Yihan Peng,Cai Zhang,Xin Wang,Xiangpan Li,Yi Yao,Qibin Song,Jing Li,Huadong Pei
DOI: https://doi.org/10.1016/j.canlet.2024.216742
IF: 9.756
2024-02-24
Cancer Letters
Abstract:O -linked-N-acetylglucosaminylation ( O -GlcNAcylation), a dynamic post-translational modification (PTM), holds profound implications in controlling various cellular processes such as cell signaling, metabolism, and epigenetic regulation that influence cancer progression and therapeutic resistance. From the therapeutic perspective, O -GlcNAc modulates drug efflux, targeting and metabolism. By integrating signals from glucose, lipid, amino acid, and nucleotide metabolic pathways, O -GlcNAc acts as a nutrient sensor and transmits signals to exerts its function on genome stability, epithelial-mesenchymal transition (EMT), cell stemness, cell apoptosis, autophagy, cell cycle. O -GlcNAc also attends to tumor microenvironment (TME) and the immune response. At present, several strategies aiming at targeting O -GlcNAcylation are under mostly preclinical evaluation, where the newly developed O -GlcNAcylation inhibitors markedly enhance therapeutic efficacy. Here we systematically outline the mechanisms through which O -GlcNAcylation influences therapy resistance and deliberate on the prospects and challenges associated with targeting O -GlcNAcylation in future cancer treatments.
oncology